Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ... Jama 313 (13), 1347-1361, 2015 | 592 | 2015 |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 455 | 2017 |
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 409 | 2017 |
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, J Dennis, ... JNCI: Journal of the National Cancer Institute 109 (7), djw302, 2017 | 351 | 2017 |
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS genetics 9 (3), e1003212, 2013 | 343 | 2013 |
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations TR Rebbeck, TM Friebel, E Friedman, U Hamann, D Huo, A Kwong, ... Human mutation 39 (5), 593-620, 2018 | 334 | 2018 |
Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 320 | 2015 |
Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants S Li, V Silvestri, G Leslie, TR Rebbeck, SL Neuhausen, JL Hopper, ... Journal of Clinical Oncology 40 (14), 1529-1541, 2022 | 208 | 2022 |
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores J Lecarpentier, V Silvestri, KB Kuchenbaecker, D Barrowdale, J Dennis, ... Journal of Clinical Oncology 35 (20), 2240-2250, 2017 | 199 | 2017 |
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes L Fachal, H Aschard, J Beesley, DR Barnes, J Allen, S Kar, KA Pooley, ... Nature genetics 52 (1), 56-73, 2020 | 173 | 2020 |
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 V Silvestri, D Barrowdale, AM Mulligan, SL Neuhausen, S Fox, BY Karlan, ... Breast Cancer Research 18, 1-13, 2016 | 151 | 2016 |
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification MT Parsons, E Tudini, H Li, E Hahnen, B Wappenschmidt, L Feliubadaló, ... Human mutation 40 (9), 1557-1578, 2019 | 140 | 2019 |
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer MA Ferreira, ER Gamazon, F Al-Ejeh, K Aittomäki, IL Andrulis, ... Nature communications 10 (1), 1741, 2019 | 135 | 2019 |
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants DR Barnes, MA Rookus, L McGuffog, G Leslie, TM Mooij, J Dennis, ... Genetics in Medicine 22 (10), 1653-1666, 2020 | 117 | 2020 |
Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review SL Rasmussen, HB Krarup, KG Sunesen, IS Pedersen, PH Madsen, ... Colorectal Disease 18 (6), 549-561, 2016 | 110 | 2016 |
Frequent Loss of Imprinting of PEG1/MEST in Invasive Breast Cancer IS Pedersen, PA Dervan, D Broderick, M Harrison, N Miller, E Delany, ... Cancer research 59 (21), 5449-5451, 1999 | 109 | 1999 |
BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers HD Meeks, H Song, K Michailidou, MK Bolla, J Dennis, Q Wang, ... Journal of the National Cancer Institute 108 (2), djv315, 2016 | 107 | 2016 |
Hypermethylated DNA, a circulating biomarker for colorectal cancer detection SL Rasmussen, HB Krarup, KG Sunesen, MB Johansen, MT Stender, ... PLoS One 12 (7), e0180809, 2017 | 93 | 2017 |
The BRCA1 c. 5096G> A p. Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA … S Moghadasi, HD Meeks, MPG Vreeswijk, LAM Janssen, Å Borg, ... Journal of medical genetics 55 (1), 15-20, 2018 | 86 | 2018 |
Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing PJ Whiley, M De La Hoya, M Thomassen, A Becker, R Brandão, ... Clinical chemistry 60 (2), 341-352, 2014 | 86 | 2014 |